To Compare the Quality of Life in Newly Diagnosed Patient's of Epilepsy on Monotherapy with Levetiracetam and Valproic Acid
Authors/Creators
- 1. Assistant Professor, Department of Pharmacology, Muzaffarnagar Medical College and Hospital, Muzaffarnagar
- 2. Assistant Professor, Department of Pharmacology, Naraina Medical College and Research Centre, Kanpur
- 3. Professor, Department of Pharmacology, Himalayan Institute of Medical Sciences, Dehradun
- 4. Professor and Head, Department of Neurology, Himalayan Institute of Medical Sciences, Dehradun
- 5. Professor, Department of Pharmacology, Muzaffarnagar Medical College and Hospital, Muzaffarnagar
Description
Background: Quality of life (QOL) is often neglected while managing epilepsy, as the main goal is to enable a person to live a seizure-free life. Epilepsy and its treatment affect the quality of life of the patient. Methods: The present study was an observational analytical study, comparing QOL in epileptic patients receiving monotherapy with either levetiracetam or valproic acid. It was conducted in the Department of Neurology, Himalayan Institute of Medical Sciences, Dehradun. Over 12 months period, 120 patients satisfying inclusion criteria were enrolled and divided into two groups based on the treating physician’s discretion. They were followed up for a period of 12 weeks. Patients were evaluated based on a QOLIE-10 self-administered questionnaire for quality of life at 0 and 12 weeks. They were also assessed for drug-related adverse effects and seizure control. Results: Significant improvement in quality of life was seen with both drugs. Levetiracetam (18.117 ± 1.967) showed a mean change significantly greater than valproic acid (11.317 ± 2.931) (p<0.05). The most common adverse event in the levetiracetam group was drowsiness; in the valproic acid group, the most common were anorexia and drowsiness. Seizure control was similar in both groups at the end of 12 weeks. Conclusions: Monotherapy with levetiracetam resulted in a better quality of life, with similar seizure control and a lesser number of adverse events as compared to valproic acid.
Abstract (English)
Background: Quality of life (QOL) is often neglected while managing epilepsy, as the main goal is to enable a person to live a seizure-free life. Epilepsy and its treatment affect the quality of life of the patient. Methods: The present study was an observational analytical study, comparing QOL in epileptic patients receiving monotherapy with either levetiracetam or valproic acid. It was conducted in the Department of Neurology, Himalayan Institute of Medical Sciences, Dehradun. Over 12 months period, 120 patients satisfying inclusion criteria were enrolled and divided into two groups based on the treating physician’s discretion. They were followed up for a period of 12 weeks. Patients were evaluated based on a QOLIE-10 self-administered questionnaire for quality of life at 0 and 12 weeks. They were also assessed for drug-related adverse effects and seizure control. Results: Significant improvement in quality of life was seen with both drugs. Levetiracetam (18.117 ± 1.967) showed a mean change significantly greater than valproic acid (11.317 ± 2.931) (p<0.05). The most common adverse event in the levetiracetam group was drowsiness; in the valproic acid group, the most common were anorexia and drowsiness. Seizure control was similar in both groups at the end of 12 weeks. Conclusions: Monotherapy with levetiracetam resulted in a better quality of life, with similar seizure control and a lesser number of adverse events as compared to valproic acid.
Files
IJPCR,Vol15,Issue3,Article214.pdf
Files
(384.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:758b822602fa4913be15857d9f7d698a
|
384.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-03-27
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue3,Article214.pdf
- Development Status
- Active
References
- 1. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013; 54(3):551–63. 2. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav. 2003;4:659–66. 3. Nelson LP, Savelli-Castillo I. New antiepileptic agents. Pediatr Dent. 2004;26:58-62. 4. Viteri C, Codina M, Cobaleda S, Lahuerta J, Barriga J, Morales MD. Quality of life in Spanish epilepsy patients on monotherapy with Lamotrigine or Valproic acid. Seizure. 2010; 19:432-38. 5. Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996; 37(6):577-82. 6. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurology. 2011;10:446-56. 7. Norsa'adah B, Zainab J, Knight A. The quality of life of people with epilepsy at a tertiary referral centre in Malaysia. Health and Quality of life Outcomes. 2013; 11: 143-48. 8. Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868-73. 9. Shanmukhi S, Sita Jayalakshmi S, Anand B. Factors Associated with Quality of Life in Adult Epilepsy Patients - a Hospital Based Study from South India. Res Neurol Int. 2015;1-5. 10. Jacoby A. Epilepsy and the quality of everyday life: findings from a study of people with well-controlled epilepsy. Soc Sci Med. 1992; 34:657-66. 11. Suresh S, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures. Epilepsy Research and Treatment. 2015;2015:1-6. 12. Marson A, Al-Kharusi A, Alwaidh M, Appleton R, Baker G, Chadwick D et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. The Lancet. 2007;369(9566):1016-26. 13. Tatum WO IV, Benbadis S, Vale FL. The neurosurgical treatment of epilepsy. Arch Fam Med. 2000;9:114 2-6. 14. Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Curr 2011;11:9-11. 15. Ahmad N, Othaman NI, Islahudin F. Medication adherence and quality oflife in epilepsy patients. Int J Pharm Pharm Sci. 2013; 5(2):401-4. 16. Bigelow J, Singh V, Singh M. Medication adherence in patients with epilepsy after a single neurologist visit in rural India. Epilepsy & Behavior. 2013;29(2):412-15. 17. Roopa BS, Narayan SS, Sharma G, Rodrigues RJ, Kulkarni C. Pattern of adverse drug reactions to antiepileptic drugs: a cross-sectional one-year survey at a tertiary care hospital. Pharmacoepidemiology and Drug Safety. 2008;17(8):807-12. 18. Das K, Banerjee M, Mondal GP, Devi LG, Singh OP, Mukherjee BB. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in urban epilepsy clinic. Seizure. 2007;16(7):601-07. 19. Tamubango Kitoko, H. Accouchement prématuré aux cliniques universitaires de Lubumbashi de 2011-2019 : fréquence et prise en charge . Journal of Medical Research and Health Sciences, 2023; 6(2): 2457–2470.